Federated Hermes’s Oramed Pharmaceuticals ORMP Stock Holding History

Federated Hermes’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-369	Closed	-$852	–	2103
2023 Q4	$852	Buy	369 +247	+202%	+$528	﹤0.01%	1985
2023 Q3	$318	Buy	+122	New	+$384	﹤0.01%	2059
2023 Q2	–	Sell	-684	Closed	-$1.49K	–	2189
2023 Q1	$1.49K	Buy	+684	New	+$2.17K	﹤0.01%	2022
2021 Q3	–	Sell	-439	Closed	-$6K	–	2289
2021 Q2	$6K	Buy	+439	New	+$5.02K	﹤0.01%	2023
2020 Q2	–	Sell	-536	Closed	-$2K	–	2340
2020 Q1	$2K	Buy	+536	New	+$2.35K	﹤0.01%	2026

Other funds holding ORMP

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes's ORMP Position: Q1 2024 in Review

Federated Hermes sold out of Oramed Pharmaceuticals (ORMP) in Q1 2024, closing a stake of 369 shares — an estimated $852 sold.

Federated Hermes first reported a position in ORMP in Q1 2020 and held it in 5 quarters. The position peaked at $6K in Q2 2021. 51 funds tracked by Wall St. Rank hold ORMP as of Q1 2024.

Federated Hermes reported no remaining Oramed Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Federated Hermes sold 369 Oramed Pharmaceuticals shares in Q1 2024, an estimated $852.
Federated Hermes first reported a position in Oramed Pharmaceuticals in Q1 2020 and held it in 5 quarters.
Federated Hermes's Oramed Pharmaceuticals position peaked at $6K in Q2 2021.
51 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2024.

Based on Federated Hermes's 13F filing for Q1 2024, filed 14 May 2024.